Drugs / pTVG-AR
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02411786 | Aug 2015 → May 2019 | prostate cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04989946 | Dec 2021 → Dec 2026 expected | prostate cancer | University of Wisconsin, Madison | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04090528 | Oct 2019 → Nov 2024 overdue | castration-resistant prostate carcinoma, metastatic malignant neoplasm | University of Wisconsin, Madison | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pTVG-AR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04090528 ↗ |
| Known as | MVI-118 | “a DNA vaccine (pTVG-AR, MVI-118)” PMID 32513836 ↗ Jun 2020 |
| Modality | Vaccine | “a DNA vaccine (pTVG-AR, MVI-118)” PMID 32513836 ↗ Jun 2020 |
| Route | Other | “Given ID” NCT02411786 ↗ |
| Target | AR | “a plasmid DNA vaccine encoding AR” NCT04989946 ↗ |